Notably, we observed that KD of USP13 had relatively less effect on the SKOV3-derived tumours regarding tumour weight (48.7% reduction, P<0.001) and number of nodules (31.2% reduction, P=0.0036; Supplementary Fig. 9c), suggesting that targeting USP13 may have therapeutic selectivity on the USP13-amplified OVCAs. The gene discussed is USP13; the disease is neoplasm.